Intravenous Efgartigimod or Intravenous Immunoglobulin in Guillain‐Barre Syndrome: An Observational Multicenter Study
Based on our preliminary findings, intravenous efgartigimod may be potentially tolerated in GBS over the short term. However, this study cannot establish comparative efficacy given the methodological limitations, and large-scale well-controlled head-to-head trials remain imperative.
Authors
- Jianfeng Luo
- Chong Sun (ORCID: https://orcid.org/0000-0001-9008-2158)
- M. Deng (ORCID: https://orcid.org/0009-0003-6644-2151)
- Jie Lin (ORCID: https://orcid.org/0000-0001-6351-3389)
- Chongbo Zhao (ORCID: https://orcid.org/0000-0001-9481-1418)
- Jianian Hu (ORCID: https://orcid.org/0000-0001-9915-9983)
- Fan Zhou (ORCID: https://orcid.org/0000-0002-0900-6965)
- Tao Li (ORCID: https://orcid.org/0000-0001-5080-3352)
- Hong-Qiao Cai (ORCID: https://orcid.org/0009-0003-5839-2908)
- Z X Li (ORCID: https://orcid.org/0000-0001-7198-8632)
Institutions
- Fudan University (CN)
- Wuhan University (CN)
- Renmin Hospital of Wuhan University (CN)
- Jingzhou Central Hospital (CN)
- Huashan Hospital (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of the Peripheral Nervous System
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1111/jns.70072
- Citations
- 1
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.39